SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-126468
Filing Date
2023-12-15
Accepted
2023-12-15 17:11:57
Documents
12
Period of Report
2023-12-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2333038d1_8k.htm   iXBRL 8-K 41625
  Complete submission text file 0001104659-23-126468.txt   219515

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA egrx-20231212.xsd EX-101.SCH 3012
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE egrx-20231212_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE egrx-20231212_pre.xml EX-101.PRE 22357
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2333038d1_8k_htm.xml XML 3324
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36306 | Film No.: 231491309
SIC: 2834 Pharmaceutical Preparations